Corporate Snapshot
AtheroNova Inc. (“AtheroNova” or “the Company”) is a biotechnology company focused on research and development of bile salt therapeutic compounds to safely dissolve or regress atherosclerotic plaque and improve patients’ lipid profiles. Atherosclerotic plaque is a buildup of fat, cholesterol, and other substances in the wall of arteries. These plaque deposits, which progressively narrow and block the arteries, are the main underlying cause of cardiovascular disease, including heart attack, stroke, and peripheral artery disease (PAD).The Company’s most advanced candidate, AHRO-001, works to reduce the incidence and severity of plaque by employing a bile salt to dissolve existing plaque deposits as well as prevent new deposits from forming. Bile salts are an FDA-approved natural compound used to dissolve gallstones, and have shown to be well tolerated with no history of safety concerns. AtheroNova believes that its therapeutic compounds’ ability to potentially regress atherosclerosis, coupled with a favorable safety and tolerance profile, provides a competitive advantage versus current therapies, which merely stabilize the disease. AHRO-001 is progressing toward Phase I human clinical trials in Russia with the support of AtheroNova’s research and development partner, Russia-based OOO CardioNova, Ltd. AtheroNova is also conducting preclinical studies to expand the use of its patent-pending technology to additional forms of cardiovascular disease that have been linked to atherosclerosis, including obesity, hypertension, diabetes, stroke, PAD, localized transdermal fat dissolution, and the dissolution of lipomas.
* The Corporate Snapshot was last updated on April 5, 2013.
Latest Research
 |
Quarterly Update
4-5-2013
|
Quarterly Update
01-31-2013
Click to View
Quarterly Update
10-19-2012
Click to View
Quarterly Update
07-16-2012
Click to View
Executive
Informational
Overview
06-06-2012
Click to View
Stock Information (AHRO-OTC)